Cargando…
Survivin-T34A: molecular mechanism and therapeutic potential
The inhibitor of apoptosis protein survivin’s threonine 34 to alanine (T34A) mutation abolishes a phosphorylation site for p34(cdc2)–cyclin B1, resulting in initiation of the mitochondrial apoptotic pathway in cancer cells; however, it has little known direct effects on normal cells. The possibility...
Autores principales: | Aspe, Jonathan R, Wall, Nathan R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024888/ https://www.ncbi.nlm.nih.gov/pubmed/21289859 http://dx.doi.org/10.2147/OTT.S15293 |
Ejemplares similares
-
Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant
por: Aspe, Jonathan R., et al.
Publicado: (2014) -
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
por: Chen, Xun, et al.
Publicado: (2016) -
Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential
por: Khan, S, et al.
Publicado: (2009) -
Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer
por: Khan, Salma, et al.
Publicado: (2012) -
Survivin – biology and potential as a therapeutic target in oncology
por: Cheung, Chun Hei Antonio, et al.
Publicado: (2013)